MergerLinks Header Logo

Announced

Completed

LumiraDx went public via SPAC merger with CA Healthcare Acquisition in a $3bn deal.

Synopsis

LumiraDx, a point of care diagnostics testing company, went public via a merger with CA Healthcare Acquisition, a special purpose acquisition company traded on Nasdaq, in a $3bn deal. “Ron and his management team have decades of entrepreneurial success in innovative diagnostics businesses and the LumiraDx Platform and testing menu offer healthcare providers and other customers major advantages over traditional central labs. LumiraDx has a clear strategy for addressing the large and underpenetrated testing market to increase next-generation POC market share. In the near-term, demand for fast, low-cost Covid-19 tests is driving strong and transformational growth for LumiraDx’s solutions,” Larry Neiterman, CAHC Chairman and CEO.

Show Details & Financials

Market Context

Sort

Search a database of more than 250,000 verified dealmakers

Receive automated updates on global transactions

Follow the activity, relationships and transactions of top dealmakers

No credit card required

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US